Literature DB >> 8518523

Renal effects of cyclosporin A in children treated for idiopathic nephrotic syndrome.

A S Tirelli1, G Paterlini, L Ghio, A Edefonti, B M Assael, A Bettinelli, G Cavanna, F Sereni.   

Abstract

Little data have been published on tubular renal function during cyclosporin A treatment in children without transplants. We studied 12 young subjects (mean age 10 years) with steroid-responsive idiopathic nephrotic syndrome and with signs of steroid toxicity. After achieving remission with prednisone 60 mg/m2, 8 children started cyclosporin A therapy (6 mg/kg/day) (group A) and 4 children were given cyclophosphamide 2.5 mg/kg/day (group B). The latter were considered as controls together with 10 other children with idiopathic nephrotic syndrome in complete remission and off therapy (group C). We monitored creatinine clearance and tubular handling of beta 2-microglobulin, sodium, phosphorus and uric acid for one year. Cyclosporin A induced a decrease in creatinine clearance with a decrease in fractional excretion of beta 2-microglobulin; sodium excretion was similar in the two treated groups and a transient decrease in fractional excretion of uric acid was seen only in patients receiving cyclosporin A. Both groups showed an increased renal threshold phosphate concentration. Our results suggest that in children, cyclosporin A therapy induces a decrease in glomerular filtration rate associated with increased reabsorption activity of proximal tubular cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8518523     DOI: 10.1111/j.1651-2227.1993.tb12723.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

Review 1.  Pharmacotherapeutic review and update of idiopathic nephrotic syndrome in children.

Authors:  Silvia Manrique-Rodríguez; Cecilia M Fernandez-Llamazares; Maria Sanjurjo-Saez
Journal:  Pharm World Sci       Date:  2010-03-13

Review 2.  Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.

Authors:  Thilo C von Groote; Gabrielle Williams; Eric H Au; Yizhi Chen; Anna T Mathew; Elisabeth M Hodson; David J Tunnicliffe
Journal:  Cochrane Database Syst Rev       Date:  2021-11-15

Review 3.  Interventions for minimal change disease in adults with nephrotic syndrome.

Authors:  Karolis Azukaitis; Suetonia C Palmer; Giovanni Fm Strippoli; Elisabeth M Hodson
Journal:  Cochrane Database Syst Rev       Date:  2022-03-01

4.  Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.

Authors:  Eiske M Dorresteijn; Joana E Kist-van Holthe; Elena N Levtchenko; Jeroen Nauta; Wim C J Hop; Albert J van der Heijden
Journal:  Pediatr Nephrol       Date:  2008-07-12       Impact factor: 3.714

5.  Effect of cyclosporin A on glomerular filtration rate in children with minimal change nephrotic syndrome.

Authors:  S A Hulton; L Jadresic; V Shah; R S Trompeter; M J Dillon; T M Barratt
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

Review 6.  Focal segmental glomerulosclerosis.

Authors:  I Ichikawa; A Fogo
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

7.  Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.

Authors:  Nicholas G Larkins; Isaac D Liu; Narelle S Willis; Jonathan C Craig; Elisabeth M Hodson
Journal:  Cochrane Database Syst Rev       Date:  2020-04-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.